Patents Assigned to GW Pharma Limited
  • Anti-tumoural effects of cannabinoid combinations
    Patent number: 8632825
    Abstract: The invention relates to the use of a combination of cannabinoids, particularly tetrahydrocannabinol (THC) and cannabidiol (CBD), in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumor, more particularly a glioma, more particularly still a glioblastoma multiforme (GBM).
    Type: Grant
    Filed: June 4, 2009
    Date of Patent: January 21, 2014
    Assignees: GW Pharma Limited, Otsuka Pharmaceutical Co., Limited
    Inventors: Guillermo Velasco Diez, Manuel Guzman Pastor, Mar Lorente, Sofia Torres, Fatima Rodriguez
  • Pharmaceutical formulation
    Patent number: 8603515
    Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: December 10, 2013
    Assignee: GW Pharma Limited
    Inventor: Brian Anthony Whittle
  • USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY
    Publication number: 20130296398
    Abstract: The invention relates to the use of cannabidiol (CBD), at a dose of greater than 300 mg/day, in combination with a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels, for use in the treatment of epilepsy. The SAED is preferably one which•modifies low-threshold or transient neuronal calcium currents,or•reduces high-frequency neuronal firing and sodium-dependent action potentials and enhances GABA effects. Preferred SAEDs are ethosuximide and valproate.
    Type: Application
    Filed: January 3, 2012
    Publication date: November 7, 2013
    Applicants: Otsuka Pharmaceutical Co., Limited, GW Pharma Limited
    Inventors: Ben Whalley, Claire Williams, Gary Stephens
  • PHARMACEUTICAL FORMULATION
    Publication number: 20130245109
    Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.
    Type: Application
    Filed: June 1, 2012
    Publication date: September 19, 2013
    Applicant: GW Pharma Limited
    Inventor: Brian Anthony Whittle
  • USE FOR CANNABINOIDS
    Publication number: 20130245110
    Abstract: The present invention relates to the use of CBD alone or in combination with another cannabinoid, in the manufacture of a pharmaceutical or neutraceutical formulation for use in controlling cholesterol levels in a subject. It also relates to the use of THCV alone or in combination with another cannabinoid, in the manufacture of a pharmaceutical or neutraceutical formulation for use in increasing energy expenditure in a subject. Furthermore the CBD alone or in combination with another cannabinoid or the THCV alone or in combination with another cannabinoid are used as part of a regime to manage or treat type I or II diabetes, obesity, dyslipidaemia, related metabolic disorders and cardiovascular disease.
    Type: Application
    Filed: January 7, 2013
    Publication date: September 19, 2013
    Applicant: GW Pharma Limited
    Inventors: Geoffrey Guy, Stephen Wright, Michael Anthony Cawthorne, Saoirse O'Sullivan
  • Pharmaceutical compositions
    Patent number: 8512767
    Abstract: The present invention relates to an improved mode of administration for cannabis and its natural and synthetic derivatives. A pharmaceutical composition suitable for sublingual aerosol or spray delivery of cannabis is provided. The formulation may be dispensed using a pump spray or the formulation may include a propellant, such as butane, 1,1,1,2-tetrafluoroethane (HFC-134a) or 1,1,1,2,3,3,3-heptafluoropropane (HFC-227). The term cannabis is used herein to refer to all physiologically active substances derived from the cannabis family of plants and synthetic cannabis analogues and derivatives, precursors, metabolites etc., or related substances having cannabis-like physiological effects.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: August 20, 2013
    Assignee: GW Pharma Limited
    Inventor: Calvin Ross
  • Pharmaceutical compositions comprising cannabigerol
    Patent number: 8481085
    Abstract: The present invention relates to the use of cannabigerol (CBG) type compounds and derivatives thereof in the treatment of mood disorders.
    Type: Grant
    Filed: June 8, 2007
    Date of Patent: July 9, 2013
    Assignee: GW Pharma Limited
    Inventors: Richard Musty, Richard Deyo
  • Pharmaceutical compositions
    Patent number: 8481091
    Abstract: The present invention relates to an improved mode of administration for cannabis and its natural and synthetic derivatives. A pharmaceutical composition suitable for sublingual aerosol or spray delivery of cannabis is provided. The formulation may be dispensed using a pump spray or the formulation may include a propellant, such as butane, 1,1,1,2-tetrafluoroethane (HFC-134a) or 1,1,1,2,3,3,3-heptafluoropropane (HFC-227). The term cannabis is used herein to refer to all physiologically active substances derived from the cannabis family of plants and synthetic cannabis analogues and derivatives, precursors, metabolites etc., or related substances having cannabis-like physiological effects.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: July 9, 2013
    Assignee: GW Pharma Limited
    Inventor: Calvin Ross
  • Pharmaceutical compositions comprising cannabichromene type compounds
    Patent number: 8470874
    Abstract: The invention relates to the use of cannabichromene type compounds and derivatives thereof in the treatment of mood disorders.
    Type: Grant
    Filed: June 24, 2004
    Date of Patent: June 25, 2013
    Assignee: GW Pharma Limited
    Inventors: Richard E. Musty, Richard Deyo
  • PHARMACEUTICAL FORMULATION
    Publication number: 20130109747
    Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.
    Type: Application
    Filed: June 1, 2012
    Publication date: May 2, 2013
    Applicant: GW Pharma Limited
    Inventor: Brian Anthony Whittle
  • PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER
    Publication number: 20130059018
    Abstract: This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon.
    Type: Application
    Filed: March 11, 2011
    Publication date: March 7, 2013
    Applicants: OTSUKA PHARMACEUTICAL CO., LIMITED, GW PHARMA LIMITED
    Inventors: Daniela Parolaro, Paola Massi, Angelo Antonio Izzo, Francesca Borelli, Gabriella Aviello, Vincenzo Di Marzo, Luciano De Petrocellis, Aniello Schiano Moriello, Alessia Ligresti, Ruth Alexandra Ross, Lesley Ann Ford, Sharon Anavi-Goffer, Manuel Guzman, Guillermo Velasco, Mar Lorente, Sofia Torres, Tetsuro Kikuchi, Geoffrey Guy, Colin Stott, Stephen Wright, Alan Sutton, David Potter, Etienne De Meijer
  • PHARMACEUTICAL COMPOSITIONS
    Publication number: 20130006182
    Abstract: The present invention relates to an improved mode of administration for cannabis and its natural and synthetic derivatives. A pharmaceutical composition suitable for sublingual aerosol or spray delivery of cannabis is provided. The formulation may be dispensed using a pump spray or the formulation may include a propellant, such as butane, 1,1,1,2-tetrafluoroethane (HFC-134a) or 1,1,1,2,3,3,3-heptafluoropropane (HFC-227). The term cannabis is used herein to refer to all physiologically active substances derived from the cannabis family of plants and synthetic cannabis analogues and derivatives, precursors, metabolites etc., or related substances having cannabis-like physiological effects.
    Type: Application
    Filed: September 7, 2012
    Publication date: January 3, 2013
    Applicant: GW Pharma Limited
    Inventor: Calvin Ross
  • PHARMACEUTICAL COMPOSITIONS
    Publication number: 20120328718
    Abstract: The present invention relates to an improved mode of administration for cannabis and its natural and synthetic derivatives. A pharmaceutical composition suitable for sublingual aerosol or spray delivery of cannabis is provided. The formulation may be dispensed using a pump spray or the formulation may include a propellant, such as butane, 1,1,1,2-tetrafluoroethane (HFC-134a) or 1,1,1,2,3,3,3-heptafluoropropane (HFC-227). The term cannabis is used herein to refer to all physiologically active substances derived from the cannabis family of plants and synthetic cannabis analogues and derivatives, precursors, metabolites etc., or related substances having cannabis-like physiological effects.
    Type: Application
    Filed: September 10, 2012
    Publication date: December 27, 2012
    Applicant: GW Pharma Limited
    Inventor: Calvin Ross
  • CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN
    Publication number: 20120245224
    Abstract: The present invention relates to the use of cannabidiol (CBD) type compounds or derivative thereof and tetrahydrocannabinol (THC) type compounds or derivative thereof in the manufacture of a medicament for the treatment of neuropathic pain. Preferably, the ratio of the CBD type compounds or derivative thereof and THC type compounds or derivative thereof is between 18:1 and 30:1. More preferably the CBD type compounds or derivative thereof and THC type compounds or derivative thereof are in the form of plant extracts.
    Type: Application
    Filed: June 7, 2012
    Publication date: September 27, 2012
    Applicant: GW Pharma Limited
    Inventors: Geoffrey Guy, Barbara Costa
  • INHIBITION OF TUMOUR CELL MIGRATION
    Publication number: 20120225136
    Abstract: The invention relates to the use of a cannabis plant extract or a cannabinoid as a pharmaceutically active agent in the inhibition of tumour cell migration.
    Type: Application
    Filed: April 5, 2012
    Publication date: September 6, 2012
    Applicant: GW Pharma Limited
    Inventors: Brian Whittle, Daniela Parolaro
  • Pharmaceutical formulation
    Patent number: 8211946
    Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.
    Type: Grant
    Filed: February 12, 2010
    Date of Patent: July 3, 2012
    Assignee: GW Pharma Limited
    Inventor: Brian Anthony Whittle
  • USE OF ONE OR A COMBINATION OF PHYTO-CANNABINOIDS IN THE TREATMENT OF EPILEPSY
    Publication number: 20120165402
    Abstract: This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD.
    Type: Application
    Filed: June 29, 2010
    Publication date: June 28, 2012
    Applicants: Otsuka Pharmaceutical Co., Limited, GW Pharma Limited
    Inventors: Ben Whalley, Gary Stephens, Claire Willaims, Geoffrey Guy, Stephen Wright, Tetsuro Kikuchi
  • COMPOSITIONS COMPRISING CANNABINOIDS FOR TREATMENT OF NAUSEA, VOMITING, EMESIS, MOTION SICKNESS OR LIKE CONDITIONS
    Publication number: 20120059062
    Abstract: Cannabinoids, in particular CBD and CBDA and their acid derivatives are provided for use as an active pharmaceutical substance in the treatment of nausea, vomiting, emesis, motion sickness. In particular extracts of cannabis plants are presented which are rich in these substances and suitable for pharmaceutical use.
    Type: Application
    Filed: August 31, 2011
    Publication date: March 8, 2012
    Applicant: GW Pharma Limited
    Inventors: Brian Whittle, Farideh Afshin Javid
  • USE OF THE PHYTOCANNABINOID CANNABIDIVARIN (CBDV) IN THE TREATMENT OF EPILEPSY
    Publication number: 20120004251
    Abstract: This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.
    Type: Application
    Filed: March 30, 2011
    Publication date: January 5, 2012
    Applicants: Otsuka Pharmaceutical Co., Limited, GW Pharma Limited
    Inventors: Ben Whalley, Claire Williams, Gary Stephens, Takashi Futamura
  • Dose dispensing system and apparatus
    Patent number: 8061351
    Abstract: A dispensing system for medication comprising a dispenser (55, 56) into which the canister (60) of medication is placed. The dispenser has a locking mechanism for selectively preventing dispensing of the medication. The system receives input data from a user and has a control device remote from the dispenser to lock the dispenser until the input data is correctly entered. The dispenser may be configured by a cartridge (100) inserted into the dispenser in place of the canister (60). The dispenser also has means for determining its location and locking the device if the dispenser is not at or within a fixed location.
    Type: Grant
    Filed: April 27, 2009
    Date of Patent: November 22, 2011
    Assignee: GW Pharma Limited
    Inventor: Rajiv Bobby Dave